Published in Immunology on August 30, 2007
KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res (2014) 0.99
Modulation of Immune System by Kaposi's Sarcoma-Associated Herpesvirus: Lessons from Viral Evasion Strategies. Front Microbiol (2012) 0.97
Molecular biology of KSHV lytic reactivation. Viruses (2015) 0.86
Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood) (2016) 0.75
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J (1963) 61.56
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Complement. First of two parts. N Engl J Med (2001) 11.16
The unactivated form of the first component of human complement, C1. Biochem J (1976) 3.12
Specificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies. J Virol (1985) 2.75
Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol (1992) 2.64
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol (1998) 2.34
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Purification of the human complement control protein C3b inactivator. Biochem J (1980) 2.06
Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A (1998) 1.97
Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev (2001) 1.67
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med (1997) 1.65
Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol (1997) 1.59
In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med (1999) 1.46
Three-dimensional structure of a complement control protein module in solution. J Mol Biol (1991) 1.44
Structure of complement receptor 2 in complex with its C3d ligand. Science (2001) 1.40
Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol (1991) 1.39
Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett (1996) 1.38
Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol (2006) 1.34
The relevance of complement to virus biology. Virology (2004) 1.29
Involvement of glycoprotein C (gC) in adsorption of herpes simplex virus type 1 (HSV-1) to the cell. Arch Virol (1991) 1.27
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol (1997) 1.22
Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol (2003) 1.15
Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. Biochem J (1983) 1.14
The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 1.14
Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem (1998) 1.09
Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Mol Immunol (1999) 1.08
The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. Mol Immunol (2006) 1.08
Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine (2003) 1.03
Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2003) 1.02
Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol (2003) 0.97
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol (1996) 0.94
DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology (2004) 0.90
The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem (2004) 0.89
Blocking measles virus infection with a recombinant soluble form of, or monoclonal antibodies against, membrane cofactor protein of complement (CD46). Immunology (1995) 0.89
Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding. J Virol (2006) 0.89
Identification of functional domains in kaposica, the complement control protein homolog of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). J Virol (2005) 0.89
Inhibition of complement components C3 and C4 by cadralazine and its active metabolite. Eur J Clin Pharmacol (1991) 0.87
The central segment of herpes simplex virus type 1 glycoprotein C (gC) is not involved in C3b binding: demonstration by using monoclonal antibodies and recombinant gC expressed in Escherichia coli. J Gen Virol (1989) 0.86
Neutralization of cytomegalovirus virions: the role of complement. J Infect Dis (1997) 0.86
Use of site-specific mutagenesis and monoclonal antibodies to map regions of CD46 that interact with measles virus H protein. Virology (1999) 0.83
Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab (2012) 2.46
Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol (2012) 2.12
C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity (2003) 2.04
The evolutionarily conserved Kaposi's sarcoma-associated herpesvirus ORF57 protein interacts with REF protein and acts as an RNA export factor. J Biol Chem (2004) 1.73
The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem (2005) 1.61
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem (2007) 1.51
Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol (2007) 1.50
A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1. J Immunol (2002) 1.47
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Rheumatoid arthritis and the complement system. Ann Med (2007) 1.42
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol (2006) 1.34
Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol (2007) 1.32
The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2. J Immunol (2004) 1.32
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem (2007) 1.30
A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet (2013) 1.29
The relevance of complement to virus biology. Virology (2004) 1.29
Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol (2008) 1.21
Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A (2005) 1.20
Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol (2009) 1.20
Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol (2009) 1.18
Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J Immunol (2009) 1.17
Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. J Virol (2006) 1.16
Functional co-operation between the Kaposi's sarcoma-associated herpesvirus ORF57 and ORF50 regulatory proteins. J Gen Virol (2004) 1.16
Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLoS Pathog (2009) 1.16
Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol (2003) 1.15
Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol (2005) 1.15
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2006) 1.15
Binding of complement inhibitor C4b-binding protein contributes to serum resistance of Porphyromonas gingivalis. J Immunol (2008) 1.14
Scabies mite inactivated serine protease paralogs inhibit the human complement system. J Immunol (2009) 1.11
Risk factors in the development of Kaposi's sarcoma. AIDS (2008) 1.11
Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology (2006) 1.10
Complement factor I in health and disease. Mol Immunol (2011) 1.10
Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol (2002) 1.10
The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. Mol Immunol (2006) 1.08
beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun (2005) 1.07
A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system. J Immunol (2012) 1.07
Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells. Immunology (2007) 1.05
Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol (2006) 1.05
Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J Biol Chem (2002) 1.05
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem (2010) 1.05
Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol (2009) 1.04
Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun (2007) 1.03
Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s. J Immunol (2012) 1.03
Complement inhibitor C4b-binding protein interacts directly with small glycoproteins of the extracellular matrix. J Immunol (2009) 1.03
Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother (2009) 1.03
Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion. J Immunol (2012) 1.02
Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2003) 1.02
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol (2007) 1.02
Staphylococcal proteases aid in evasion of the human complement system. J Innate Immun (2013) 1.02
Novel scabies mite serpins inhibit the three pathways of the human complement system. PLoS One (2012) 1.02
Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. Antimicrob Agents Chemother (2009) 1.01
Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. J Gen Virol (2003) 1.01
An interaction between KSHV ORF57 and UIF provides mRNA-adaptor redundancy in herpesvirus intronless mRNA export. PLoS Pathog (2011) 1.01
The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. J Biol Chem (2004) 1.00
Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol (2007) 0.99
Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation (2009) 0.98
Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. J Biol Chem (2013) 0.98
Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex. Mol Microbiol (2011) 0.98
C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol (2008) 0.97
Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol Immunol (2009) 0.97
Early complementopathy after multiple injuries in humans. Shock (2012) 0.97
Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. J Immunol (2005) 0.97
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein. Biochemistry (2002) 0.96
Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity. Mol Microbiol (2013) 0.96
Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line. J Virol (2011) 0.96
Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J Biol Chem (2005) 0.96
Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Mol Immunol (2008) 0.95
Haemophilus influenzae interacts with the human complement inhibitor factor H. J Immunol (2008) 0.95
Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol (2010) 0.95
Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. Mol Microbiol (2010) 0.94
Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect Immun (2007) 0.94
Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol (2007) 0.94
Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther (2013) 0.94
Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. J Infect Dis (2011) 0.93
UPF2 is a critical regulator of liver development, function and regeneration. PLoS One (2010) 0.93
Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology (2011) 0.93
Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One (2013) 0.92
The viral interferon regulatory factors of kaposi's sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3. J Virol (2012) 0.92
Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol (2005) 0.92
Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest (2003) 0.92
Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem (2009) 0.92
Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int (2002) 0.92
Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis (2006) 0.92
Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Lett (2011) 0.92
Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis (2004) 0.91
Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem (2012) 0.91
Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H. Protein Sci (2004) 0.91
C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med (2005) 0.91